Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial
Study Meets Co-Primary Endpoints: Overall Survival and Progression-Free Survival Benefit
Plexxikon’s U.S. Patent for PLX4032 Issues
Berkeley, CA — January 18, 2011 – Plexxikon Inc. today announced positive data from an interim analysis of the BRIM3 trial, a large multi‐ center Phase 3 clinical study of PLX4032 (RG7204) in patients with previously untreated metastatic melanoma with the BRAF mutation. Patients treated with PLX4032 had an improved overall survival (OS) compared to patients treated with dacarbazine, the current standard of care. In addition, these patientslived longer on average without their disease getting worse, as measured by progression‐free survival (PFS). PLX4032 is an oral, novel kinase inhibitor that targets the oncogenic BRAF mutation.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.